X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES ALEMBIC PHARMA JUBILANT LIFE SCIENCES/
ALEMBIC PHARMA
 
P/E (TTM) x 13.0 17.1 75.9% View Chart
P/BV x 1.8 3.7 49.1% View Chart
Dividend Yield % 0.6 1.0 62.4%  

Financials

 JUBILANT LIFE SCIENCES   ALEMBIC PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-18
ALEMBIC PHARMA
Mar-19
JUBILANT LIFE SCIENCES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,039664 156.5%   
Low Rs600412 145.5%   
Sales per share (Unadj.) Rs482.6208.7 231.2%  
Earnings per share (Unadj.) Rs40.731.0 131.4%  
Cash flow per share (Unadj.) Rs67.437.1 181.5%  
Dividends per share (Unadj.) Rs3.005.50 54.5%  
Dividend yield (eoy) %0.41.0 35.8%  
Book value per share (Unadj.) Rs262.3144.2 181.9%  
Shares outstanding (eoy) m155.79188.52 82.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.72.6 65.9%   
Avg P/E ratio x20.117.4 115.9%  
P/CF ratio (eoy) x12.214.5 83.9%  
Price / Book Value ratio x3.13.7 83.7%  
Dividend payout %7.417.7 41.5%   
Avg Mkt Cap Rs m127,670101,461 125.8%   
No. of employees `0002.4NA-   
Total wages/salary Rs m15,5597,467 208.4%   
Avg. sales/employee Rs Th30,861.4NM-  
Avg. wages/employee Rs Th6,387.0NM-  
Avg. net profit/employee Rs Th2,604.4NM-  
INCOME DATA
Net Sales Rs m75,17839,347 191.1%  
Other income Rs m40094 426.8%   
Total revenues Rs m75,57939,441 191.6%   
Gross profit Rs m15,1848,736 173.8%  
Depreciation Rs m4,1511,152 360.2%   
Interest Rs m2,843184 1,544.2%   
Profit before tax Rs m8,5917,493 114.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2471,568 143.3%   
Profit after tax Rs m6,3445,844 108.6%  
Gross profit margin %20.222.2 91.0%  
Effective tax rate %26.220.9 125.0%   
Net profit margin %8.414.9 56.8%  
BALANCE SHEET DATA
Current assets Rs m31,89819,577 162.9%   
Current liabilities Rs m20,04714,896 134.6%   
Net working cap to sales %15.811.9 132.5%  
Current ratio x1.61.3 121.1%  
Inventory Days Days6890 75.3%  
Debtors Days Days5545 121.1%  
Net fixed assets Rs m60,71527,097 224.1%   
Share capital Rs m156377 41.3%   
"Free" reserves Rs m40,71026,811 151.8%   
Net worth Rs m40,86527,188 150.3%   
Long term debt Rs m30,4784,993 610.4%   
Total assets Rs m96,17647,778 201.3%  
Interest coverage x4.041.7 9.6%   
Debt to equity ratio x0.70.2 406.1%  
Sales to assets ratio x0.80.8 94.9%   
Return on assets %9.612.6 75.7%  
Return on equity %15.521.5 72.2%  
Return on capital %16.023.6 67.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,40219,453 74.0%   
Fx outflow Rs m12,0446,065 198.6%   
Net fx Rs m2,35813,388 17.6%   
CASH FLOW
From Operations Rs m13,0328,120 160.5%  
From Investments Rs m-6,177-7,556 81.7%  
From Financial Activity Rs m-9,011590 -1,526.3%  
Net Cashflow Rs m-2,1231,153 -184.0%  

Share Holding

Indian Promoters % 45.6 74.1 61.5%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 2.9 300.0%  
FIIs % 21.2 9.1 233.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 13.9 151.8%  
Shareholders   23,815 49,328 48.3%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Easing of WPI Inflation; Key Q1FY20 Results; Global Stock Market Drivers and Top Stocks in Action(Pre-Open)

On Monday, the Indian share markets ended in the positive territory. The BSE Sensex settled 160 points higher at 38,897 levels with Infosys, Sun Pharma, Tech Mahindra and Maruti being the top gainers.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jul 16, 2019 09:27 AM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS